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scored on a 0 (no difficulty) to 10 (unable to do) numerical rating scale. sIFA items 
are aligned with the functional impact of sIBM described in the literature/expert 
review and identified as relevant and important to sIBM patients. The draft concep-
tual framework includes items related to upper extremity, lower extremity, general 
function and swallowing. Cognitive testing of paper and ePRO versions support 
the use of this tool in a broad functional range of sIBM patients. CONCLUSIONS: 
The sIFA is the first content valid tool developed specifically for use in the func-
tional assessment of treatment benefit in sIBM patients aligned with the FDA PRO 
Guidance. Psychometric evaluation is underway.
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OBJECTIVES: To identify and review the suitability of cystic fibrosis (CF)-specific 
clinical outcome assessments (COAs) for clinical trial assessment of novel CF thera-
pies and to support product labelling. METHODS: CF-specific COAs were identified 
through an in-depth literature search using pre-defined search terms and via clini-
caltrials.gov. COA utilization in CF clinical trials and previous success in supporting 
product labelling was also explored. In line with best-practice, conceptual coverage 
of identified COAs was assessed by mapping items to a patient-centered conceptual 
model of CF symptoms and impacts. COAs with the most comprehensive conceptual 
coverage were further evaluated for content validity, psychometric properties and 
feasibility of use. RESULTS: Nine CF-specific COAs were identified; Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) [pediatric 6-11/12-13 years, 14+ years and parent-
report 6-13 years] and Cystic Fibrosis Respiratory Symptom Diary (CFRSD) were 
selected for in-depth review. CFQ-R 14+ provided the most comprehensive concep-
tual coverage, assessing 52% of patient-centered symptom concepts and 50% impact 
concepts. Pediatric and parent-reported versions of CFQ-R assessed fewer concepts. 
All versions of CFQ-R have acceptable psychometric properties and are linguistically 
validated in > 30 languages. CFQ-R has also supported previous EMA and FDA label 
claims for respiratory symptoms. Limitations include the acceptability of a 2-week 
recall period and inconsistencies in concepts measured across pediatric and adult 
versions. CFRSD provides a comprehensive assessment of 83% of acute respiratory 
symptoms and 32% of acute impacts and is currently under evaluation for FDA Drug 
Development Tool qualification by FDA. The respiratory symptom score has excel-
lent psychometric properties; impact items are yet to be validated. CONCLUSIONS: 
Although 9 CF-specific COAs were identified in this study, only the CFQ-R measures 
and CFRSD appear potentially suitable for assessment of CF-related symptoms and 
impacts in CF clinical trials. Further data relating to content validity of CFQ-R may 
be required to support future labelling approvals.
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OBJECTIVES: The 39-item Parkinson’s Disease Questionnaire (PDQ-39) is the most 
thoroughly validated and extensively used self-report measure for the assessment 
of health-related quality of life in people with Parkinson’s (PwP). The measure has 
been shown to possess sound psychometric properties and its use is widely recom-
mended. Given the extent of its use and increasing emphasis on electronic data 
capture, a web based version of the PDQ-39, the ePDQ, has been developed. The aim 
here is to present reliability and validity data that confirm the psychometric quality 
of the ePDQ. METHODS: Recruitment of participants was undertaken with the sup-
port of Parkinson’s UK. Participants were emailed a unique link to an online survey 
containing the ePDQ and demographic questions. RESULTS: A total of 118 PwP (66 
males, 52 females) fully completed the ePDQ, a response rate of 91.4%. The mean age 
was 63.48 years, mean disease duration 5.73 years and mean age at diagnosis 57.69 
years. Score reliability was assessed by item-total correlations which ranged from 
0.34 to 0.90. Cronbach’s alpha was calculated at between 0.64 and 0.95 for the eight 
domains of the ePDQ. Construct validity was assessed by comparing group means 
for disease duration and gender and all previously hypothesised differences were 
confirmed. Furthermore, a higher order factor analysis confirmed the appropriate-
ness of calculating a summary score index. CONCLUSIONS: Data indicates that the 
ePDQ possesses appropriate levels of reliability and validity and largely mirrors the 
psychometric properties of the paper-based version.
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OBJECTIVES: Over-the-counter (OTC) sleep aids are widely self-administered and 
are generally safe, but their primary ingredients (diphenhydramine and doxylamine 
(DPH/DOX)) may pose risks, especially in older adults who may use these products 
outside of their label recommendations. This analysis characterizes the use of DPH/
DOX for sleep disturbances by age and sex in older American adults. METHODS: 
Data were taken from the 2013 US National Health and Wellness Survey (NHWS), a 
cross-sectional, internet-based, IRB-approved annual survey of adults (N= 75,000). 
Stratified sampling was used to represent the demographic make-up of the general 
population in age, sex, and ethnicity. Weights were applied using age, sex, eth-
nicity, and education to reflect the US population. Respondents reporting regular 
sleeplessness symptoms and insomnia/sleep difficulties (SD) were included in the 
analysis. Comparisons between sexes were made using chi-square tests for cat-
egorical variables and t-tests for continuous variables. RESULTS: Of the projected 
41.3 M (n= 16,500) adults age ≥ 65, 15% (3.8 M age 65-74; 2.6 M age 75+) reported 
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OBJECTIVES: Patients with rare genetic diseases often experience a diagnostic odys-
sey; no diagnosis or a delay in obtaining a diagnosis, due to lengthy diagnostic 
work-ups. Whole-exome sequencing (WES) can rapidly identify the mutation(s) 
responsible for rare, single-gene diseases. Before incorporating this new technology 
into clinical practice, we must understand the value of diagnostic information. We 
aimed to identify key attributes surrounding the value of a diagnosis to develop a 
discrete choice experiment (DCE) survey to estimate the value of WES diagnostic 
information to parents of children with rare diseases. METHODS: We used a multi-
phase, mixed-methods approach to identify key attributes and levels. We conducted 
a literature review to identify an extensive list of candidate attributes. We used 
results from focus groups with parents of children (n= 15) and adults (n= 8) with 
rare diseases to identify additional attributes. Candidate attributes were refined 
by consultation with research team members (including medical geneticists). The 
DCE survey was pre-tested in a sample of parents of children with rare diseases 
(n= 5) and attributes were further refined. RESULTS: The DCE included six attributes, 
each with four levels: type of diagnostic (genomic sequencing, other genetic testing, 
operative procedures, series of tests and procedures); chance of a diagnosis (1/10, 
4/10, 6/10, 9/10); negative impact of diagnostic test results (lifestyle restrictions, 
victim of discrimination, labeled by others, no impact); positive impact of diagnos-
tic test results (lead to therapy); out-of-pocket cost ($250, $1000, $5000, $10,000); 
time to obtain a diagnosis (6 months, 3 years, 5 years, 10 years). CONCLUSIONS: 
The survey will be administered to n= 300 parents of children with rare diseases 
(diagnosed and undiagnosed) to evaluate willingness-to-pay for: WES, a diagnosis, 
and a faster diagnosis.
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OBJECTIVES: To identify and appraise the reporting on psychometric properties of 
selected patient reported outcome measures (PROs) used in multiple sclerosis (MS) 
Phase IV trials, and to identify PROs potentially suitable for Phase IV use. METHODS: 
We systematically searched PubMed, Clinicaltrials.gov, and MS conferences from 
2009 onwards to identify PROs used in MS Phase IV trials. For further assessment, 
we selected PROs on key MS concepts: health-related quality of life (HRQoL), mood/
depression, fatigue, and cognition. These PROs were appraised in the context of the 
U.S Food and Drug Administration guidance for work reporting on psychometric 
properties (validity, reliability, and responsiveness). RESULTS: A total of 24 PROs on 
the selected concepts were identified from 30 studies. PROs were MS-specific for 7 
of 13 HRQoL, 1 of 7 mood/depression, and 1 of 4 fatigue measures. No study reported 
using PROs that independently measure cognition, although most HRQoL and 
fatigue PROs have a mental/cognition subcomponent. Modern psychometric analy-
ses were conducted on MS International Quality of Life Questionnaire (MusiQoL), 
MS Impact Scale-29 (MSIS-29), MS Neuropsychological Screening Questionnaire 
(MSNQ), Fatigue Severity Scale (FSS), and Modified Fatigue Impact Scale (MFIS). 
MS-specific HRQoL PROs were well-validated and are potentially useful in trial set-
tings, namely MusiQoL, MSIS-29 and Hamburg QoL Questionnaire MS (HAQUAMS). 
The MSNQ, measuring mood/depression, reported reliability and content validity 
but have unknown construct validity and responsiveness. Generic PROs for mood/
depression generally lacked information on psychometric performance in MS 
patients. Among PROs measuring fatigue, FSS and MFIS appeared most promising 
for trial use, but did not have content validity for MS patients. CONCLUSIONS: 
Of the identified PROs, only a few were well-validated. More work is warranted to 
assess the suitability of insufficiently validated PROs for use in MS trials. Also, since 
mental deficit is a key concept in MS, future Phase IV trials should consider using 
PROs measuring cognition.
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OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups with the knee exten-
sors and wrist/finger flexors frequently involved as well as dysphagic processes. 
Progressive weakness results in a loss of independence and the need for assistive 
devices and supportive care. While no pharmacological treatments for sIBM are 
currently marketed, clinical trials are underway. To assess the potential treatment 
benefit of new therapies and track clinical progression, a patient-reported measure 
(PROM) of physical function, the siBM Physical functioning assessment (sIFA), was 
developed. METHODS: The sIFA was rigorously developed in accordance with the 
FDA PRO Guidance. This included literature review, medical expert and direct patient 
input. A single-visit, observational study involving sequential concept elicitation 
and cognitive debriefing interviews was conducted. Standard qualitative analytical 
methods were employed to analyze interview data and generate and pilot-test ques-
tionnaire items. RESULTS: Twenty concept elicitation and 19 cognitive debriefing 
interviews were conducted as well as consultation with six sIBM expert physicians. 
sIBM patients (n= 39) varied in age (mean= 67; range 46-81), duration of diagnosis 
(1 – 18 years), and functional impairment. The resultant PROM consists of 11 items 
